Cargando…
Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients
Dupilumab, a monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adult patients with moderate-to-severe atopic dermatitis, inhibits interleukins 4 and 13. It is an effective treatment option for atopic dermatitis, but facial redness has been reported as an unex...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Asia Pacific Association of Allergy, Asthma and Clinical Immunology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819416/ https://www.ncbi.nlm.nih.gov/pubmed/35174052 http://dx.doi.org/10.5415/apallergy.2022.12.e1 |